Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

View All Documentation

C0694990

Cefuroxime Axetil

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

[6R-[6α,7β(Z)]]-3-[[(Aminocarbonyl)oxy]methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid 1-(acetyloxy)ethyl ester

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C20H22N4O10S
Numéro CAS:
64544-07-6
Poids moléculaire :
510.47
Numéro MDL:
MFCD00864991
Code UNSPSC :
41116107
ID de substance PubChem :
329774816
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

cefuroxime

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

O=C1[C@@H](NC(/C(C2=CC=CO2)=N\OC)=O)[C@]3([H])N1C(C(OC(C)OC(C)=O)=O)=C(COC(N)=O)CS3

InChI

1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1

Clé InChI

KEJCWVGMRLCZQQ-YJBYXUATSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Cefuroxime Axetil EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1098209

Cefuroxime sodium, United States Pharmacopeia (USP) Reference Standard

1098220

Cefuroxime Axetil, United States Pharmacopeia (USP) Reference Standard

1098231

Cefuroxime Axetil Delta-3-Isomers, United States Pharmacopeia (USP) Reference Standard

C0695000

Cefuroxime sodium, European Pharmacopoeia (EP) Reference Standard

1098253

Cefuroxime Axetil E-isomers, United States Pharmacopeia (USP) Reference Standard

BP502

Cefuroxime Axetil, British Pharmacopoeia (BP) Reference Standard

BP925

Cefuroxime sodium, British Pharmacopoeia (BP) Reference Standard

PHR2683

Cefuroxime Sodium, certified reference material, pharmaceutical secondary standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H317,H334

Classification des risques

Resp. Sens. 1 - Skin Sens. 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

L J Scott et al.
Drugs, 61(10), 1455-1500 (2001-09-18)
Cefuroxime axetil, a prodrug of the cephalosporin cefuroxime, has proven in vitro antibacterial activity against several gram-positive and gram-negative organisms, including those most frequently associated with various common community-acquired infections. In numerous randomised, controlled trials, 5 to 10 days' treatment
P Gehanno et al.
The British journal of clinical practice, 49(1), 28-32 (1995-01-01)
Recent resurgence in serious streptococcal infections and rising failure rates with the standard 10-day course of therapy with penicillin V for group A beta-haemolytic streptococcus (GABHS)-associated tonsillopharyngitis (pharyngitis and/or tonsillitis) have heightened interest in alternative treatments for this infection. Reasons
H J Manley et al.
Clinical nephrology, 49(4), 268-270 (1998-05-16)
Cefuroxime axetil has been associated with few reported adverse effects. We report a case of bilateral renal cortical necrosis in a female after receiving 7 doses over 4 treatment days. The patient presented with worsening symptoms consisting of arthralgias, pruritus
M A Marx et al.
Drug intelligence & clinical pharmacy, 22(9), 651-658 (1988-09-01)
Cefuroxime axetil is a orally active prodrug formulation of cefuroxime, which upon absorption undergoes immediate deesterification to free cefuroxime. Cefuroxime axetil offers an in vitro antibacterial spectrum against many gram-positive and some gram-negative organisms. Its beta-lactamase stability makes it useful
C M Perry et al.
Drugs, 52(1), 125-158 (1996-07-01)
Cefuroxime axetil is an oral cephalosporin which is rapidly hydrolysed to the active parent compound, cefuroxime. Cefuroxime has a broad spectrum of in vitro antibacterial activity which encompasses methicillin-sensitive staphylococci and the common respiratory pathogens Streptococcus pneumoniae, Haemophilus influenzae, Moraxella
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique